Effect of Sodium-glucose Cotransporter 2 Inhibitors on Serum Low-density Lipoprotein Cholesterol in Japanese Patients with Type 2 Diabetes Mellitus

Overview

Journal J Diabetes Investig

Specialty Endocrinology

Date 2024 Mar 9

PMID 38459768

Authors

Tasuku Imada

Naoto Katakami

Hirotaka Watanabe

Shuhei Nishina

Shugo Sasaki

Mitsuyoshi Takahara

Iichiro Shimomura

Tsunehiko Yamamoto

Affiliations

Soon will be listed here.

Abstract

Aims/introduction: We aimed to evaluate factors that influence changes in blood low-density lipoprotein cholesterol (LDL-C) levels after treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors in Japanese patients with type 2 diabetes.

Materials And Methods: We retrospectively analyzed clinical data of outpatients newly initiated on SGLT2 inhibitors (n = 176) and other oral antidiabetic drugs (n = 227). The patients were classified into four subgroups according to statin administration and baseline LDL-C levels (<120 or ≥120 mg/dL). Clinical characteristics were compared among the subgroups. Multivariate analysis was carried out to identify factors contributing to changes in LDL-C.

Results: The median follow-up period was 13.0 weeks (range 11.9-14.1 weeks, min 8 weeks, maximum 16 weeks) in the SGLT2i group, and 12.0 weeks (range 10.0-14.0 weeks, min 8 weeks, maximum 16 weeks) in the control group. Both groups showed a significant decrease in LDL-C (SGLT2i group -3.8 ± 24.7 mg/dL, control group -3.4 ± 15.0 mg/dL). Multivariate regression analyses showed that in both groups, the change in LDL-C depended on statin use and baseline LDL-C levels. Stratified analyses showed that LDL-C level was significantly decreased in statin users with baseline LDL-C ≥120 mg/dL (from 148.9 ± 33.5 to 109.3 ± 17.9 mg/dL, P = 0.002), and significantly increased in statin non-users with baseline LDL-C <120 mg/dL (from 96.3 ± 27.3 to 104.7 ± 24.8 mg/dL, P = 0.002). These changes were more characteristic for SGLT2 inhibitors than for other oral antidiabetic drugs (P for interaction = 0.010 and <0.001, respectively).

Conclusions: LDL-C levels and statin medication at baseline influence changes in LDL-C after SGLT2 inhibitors treatment in Japanese patients with type 2 diabetes.

Citing Articles

Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients.

Katsuyama H, Horinaka S, Hakoshima M, Adachi H, Yanai H J Clin Med. 2024; 13(16).

PMID: 39201071 PMC: 11355713. DOI: 10.3390/jcm13164929.

References

Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R . Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016; 65(5):1190-5. DOI: 10.2337/db15-1356. View

Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y . Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study. Cardiovasc Diabetol. 2020; 19(1):110. PMC: 7350187. DOI: 10.1186/s12933-020-01079-4. View

Newport M, VanItallie T, Kashiwaya Y, Todd King M, Veech R . A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's disease. Alzheimers Dement. 2014; 11(1):99-103. PMC: 4300286. DOI: 10.1016/j.jalz.2014.01.006. View

Tanaka M, Yamakage H, Inoue T, Odori S, Kusakabe T, Shimatsu A . Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial. Intern Med. 2020; 59(5):601-609. PMC: 7086326. DOI: 10.2169/internalmedicine.3473-19. View

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

Storgaard H, Gluud L, Bennett C, Grondahl M, Christensen M, Knop F . Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(11):e0166125. PMC: 5106000. DOI: 10.1371/journal.pone.0166125. View

Inagaki N, Kondo K, Yoshinari T, Kuki H . Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study. J Diabetes Investig. 2015; 6(2):210-8. PMC: 4364856. DOI: 10.1111/jdi.12266. View

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

Briand F, Mayoux E, Brousseau E, Burr N, Urbain I, Costard C . Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism. Diabetes. 2016; 65(7):2032-8. DOI: 10.2337/db16-0049. View

10.

Inagaki N, Goda M, Yokota S, Maruyama N, Iijima H . Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Adv Ther. 2015; 32(11):1085-103. PMC: 4662712. DOI: 10.1007/s12325-015-0255-8. View

11.

Rau M, Thiele K, Hartmann N, Mollmann J, Wied S, Bohm M . Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study. Atherosclerosis. 2021; 330:8-13. DOI: 10.1016/j.atherosclerosis.2021.06.915. View

12.

Sarwar N, Gao P, Kondapally Seshasai S, Gobin R, Kaptoge S, Di Angelantonio E . Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733):2215-22. PMC: 2904878. DOI: 10.1016/S0140-6736(10)60484-9. View

13.

Terra S, Focht K, Davies M, Frias J, Derosa G, Darekar A . Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017; 19(5):721-728. DOI: 10.1111/dom.12888. View

14.

Summerhill V, Grechko A, Yet S, Sobenin I, Orekhov A . The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis. Int J Mol Sci. 2019; 20(14). PMC: 6678182. DOI: 10.3390/ijms20143561. View

15.

Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S . Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015; 38(3):365-72. DOI: 10.2337/dc14-0666. View

16.

Toyota Y, Yamamura T, Miyake Y, Yamamoto A . Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia. Atherosclerosis. 1999; 147(1):77-86. DOI: 10.1016/s0021-9150(99)00166-5. View

17.

Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A . Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017; 16(1):8. PMC: 5237208. DOI: 10.1186/s12933-016-0491-5. View

18.

Davies M, DAlessio D, Fradkin J, Kernan W, Mathieu C, Mingrone G . Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12):2669-2701. PMC: 6245208. DOI: 10.2337/dci18-0033. View

19.

Bando Y, Tohyama H, Aoki K, Kanehara H, Hisada A, Okafuji K . Ipragliflozin lowers small, dense low-density lipoprotein cholesterol levels in Japanese patients with type 2 diabetes mellitus. J Clin Transl Endocrinol. 2017; 6:1-7. PMC: 5644427. DOI: 10.1016/j.jcte.2016.06.001. View

20.

Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H . Japanese Clinical Practice Guideline for Diabetes 2019. Diabetol Int. 2020; 11(3):165-223. PMC: 7387396. DOI: 10.1007/s13340-020-00439-5. View